top of page

Register: NET Cancer Day Symposium in Las Vegas

TAKE ACTION

Home
About Us
Education
Support for Patients & Caregivers
Resource Guide
Clinical Trials Guide
More

Use tab to navigate through the menu items.

Neuroendocrine Carcinomas (NECs) & Grade 3 Neuroendocrine Tumors (NETs)

Neuroendocrine Carcinomas (NECs) & Grade 3 Neuroendocrine Tumors (NETs)

Grade 3 NET

Alpha PRRT with Pb-212 VMT
Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs
BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors
CHM-2101 CAR-T cell for GI Cancers
COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS
ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs
DAREON™-7: DLL-3 For Advanced Neuroendocrine Cancers
IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Olaparib in GEP-NETs
Lu-177 DOTATATE + Sunitinib in PNETs
SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029)
STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors
SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)
SWOG S2104: Adjuvant CAPTEM for High Risk pNET
Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Neuroendocrine Carcinoma (NEC)

225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC
Alpha PRRT with Pb-212 VMT
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors
DAREON®-NEC-1: Obrixtamig Plus Chemotherapy vs Standard Chemotherapy in Advanced epNEC
DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers
DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)
IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)
SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum
Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC
Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms
ZL-1310 (DLL3-targeted ADC) in DLL3+ Tumors

NEUROENDOCRINE CANCER FOUNDATION

Mailing Address:

PO BOX 370466

DENVER, CO 80237

info@ncf.net

TERMS & CONDITIONS

© 2025 by Neuroendocrine Cancer Foundation

bottom of page